Increased Pressure from Patent Expirations to Drive Pharmaceutical Mergers and Acquisitions in 2026

The pharmaceutical industry is bracing itself for the impact of the looming patent cliff, which could expose up to $300 billion in annual drug sales to loss of exclusivity by 2032. Despite this significant challenge on the horizon, the momentum in pharmaceutical mergers and acquisitions (M&A) is expected to remain steady in 2026. Companies are actively pursuing acquisitions to address the persistent portfolio growth gaps they are facing in the industry.

Dan Chancellor, Norstella’s vice president of thought leadership, has shed light on the ongoing situation in the Pharma Commerce video interview. According to Chancellor, the impact of the deals being made today should be viewed with a long-term perspective. Most acquisitions influence a company’s performance three to five years down the line, rather than immediately reacting to the looming patent cliff.

Large pharmaceutical companies have been well aware of the risks associated with the patent cliff for several years now. Consequently, they have already factored this into their portfolio strategies. The current and upcoming deal activity is driven by forward-looking pipeline and revenue needs, rather than merely reacting to exclusivity losses.

While 2025 saw a surge in M&A activity, 2024 was relatively quiet, indicating that deal flow is influenced more by the availability and quality of viable assets rather than urgency alone. Despite having sufficient cash and transaction capabilities, pharmaceutical companies remain selective in their acquisitions, prioritizing assets that strategically fit their portfolios.

In addition to patent expirations, companies are facing broader growth gaps due to maturing portfolios and a lack of late-stage pipeline output. Analysis of the top 12 pharmaceutical companies reveals that most are projected to grow below the market average of 7%, highlighting the revenue shortfalls they are expected to face by the end of the decade.

M&A remains a critical tool for addressing these growth gaps, alongside lifecycle management and internal research and development (R&D) investments. As a result, 2026 is expected to see a continuation of steady dealmaking, rather than a sudden surge in activity, as companies use acquisitions to bolster future growth.

Chancellor emphasizes that the deals being made now will have a more significant impact on the industry in the coming years, rather than an immediate effect in 2026. Despite the challenges posed by the patent cliff and growth gaps, pharmaceutical companies are poised to navigate these obstacles through strategic M&A activities that align with their long-term growth objectives.